Aviragen Therapeutics, Inc., formerly Biota Pharmaceuticals Inc., is a biopharmaceutical company. The Company is focused on the discovery and development of direct-acting antivirals to treat infections. It has approximately four product candidates in clinical development that address viral infections that have limited therapeutic options. Its product candidates include vapendavir, which is an oral treatment for human rhinovirus infections in moderate-to-severe asthmatics that is being evaluated in its Phase IIb SPIRITUS trial; BTA074, a Phase II topical antiviral treatment for genital warts caused by human papillomavirus types 6 and 11; BTA585, an oral fusion protein inhibitor in Phase IIa development for the treatment and prevention of respiratory syncytial virus (RSV)-A and RSV-B infections, and laninamivir octanoate in Phase II development for the treatment of influenza A and B infections. It also has preclinical RSV non-fusion inhibitor program.